Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PDE4A | P27815 | 3/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718494 | 0.84 | SLC40A1 (0.47) | ALDH1A1PDE4APDE4CPDE4DEGLN1 | |
| SCHEMBL19358748 | 0.84 | ALDH1A1 (0.54) | ALDH1A1PDE4APDE4CPDE4DLMNA | |
| SCHEMBL2015013 | 0.81 | HIF1A (0.44) | ALDH1A1PDE4APDE4CPDE4DLMNA | |
| SCHEMBL2013023 | 0.79 | EGLN1 (0.46) | ALDH1A1EGLN1 | |
| SCHEMBL643192 | 0.76 | ALDH1A1 (0.46) | ALDH1A1LMNAL3MBTL1EGLN1KDM4E | |
| SCHEMBL2017299 | 0.76 | ALDH1A1 (0.60) | ALDH1A1EGLN1 | |
| SCHEMBL3922378 | 0.74 | PARP1 (0.55) | ALDH1A1LMNAL3MBTL1KDM4EALOX12 | |
| SCHEMBL4149669 | 0.74 | PDE4A (0.50) | PDE4APDE4CPDE4DLMNAKDM4E | |
| SCHEMBL18318080 | 0.74 | PDE4A (0.45) | ALDH1A1PDE4APDE4CPDE4DLMNA | |
| SCHEMBL21358355 | 0.71 | L3MBTL1 (0.46) | L3MBTL1KDM4EMAPTHTTMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | ALDH1A1 3722/4885PDE4A 2583/4885PDE4C 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.